Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ArvinasI-MabHyperaAgios PharmaceuticalsFibroGen
SymbolNASDAQ:ARVNNASDAQ:IMABOTCMKTS:HYPMYNASDAQ:AGIONASDAQ:FGEN
Price Information
Current Price$64.69$57.00$6.27$54.69$19.91
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.51.20.91.31.8
Analysis Score3.52.50.02.44.1
Community Score2.33.32.62.72.5
Dividend Score0.00.00.80.00.0
Ownership Score1.70.00.01.71.7
Earnings & Valuation Score0.00.01.30.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$106.45$70.00N/A$64.64$45.83
% Upside from Price Target64.56% upside22.81% upsideN/A18.19% upside130.20% upside
Trade Information
Market Cap$3.16 billion$4.10 billion$3.97 billion$3.82 billion$1.82 billion
Beta2.14N/A0.961.81.59
Average Volume487,086358,16915,865782,3011,475,040
Sales & Book Value
Annual Revenue$42.98 million$4.31 million$834.89 million$117.91 million$256.58 million
Price / Sales73.56951.504.7632.387.14
CashflowN/AN/A$0.51 per shareN/AN/A
Price / CashN/AN/A12.39N/AN/A
Book Value$6.72 per share$3.34 per share$3.49 per share$10.88 per share$6.14 per share
Price / Book9.6317.071.805.033.24
Profitability
Net Income$-70,290,000.00$-208,560,000.00$294.97 million$-411,470,000.00$-76,970,000.00
EPS($2.13)($28.90)N/A($6.86)($0.89)
Trailing P/E RatioN/AN/A14.58N/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-403.77%N/AN/A-170.65%-191.78%
Return on Equity (ROE)-46.99%N/AN/A-57.63%-48.19%
Return on Assets (ROA)-35.34%N/AN/A-37.15%-27.72%
Dividend
Annual PayoutN/AN/A$0.14N/AN/A
Dividend YieldN/AN/A2.23%N/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.01%N/AN/AN/AN/A
Current Ratio6.53%N/AN/A9.59%6.23%
Quick Ratio6.53%N/AN/A9.43%6.13%
Ownership Information
Institutional Ownership Percentage75.68%16.64%N/A92.93%75.05%
Insider Ownership Percentage10.99%N/AN/A3.16%3.39%
Miscellaneous
Employees1331858,918562599
Shares Outstanding48.87 million71.95 million633.42 million69.81 million92.07 million
Next Earnings Date4/27/2021 (Estimated)N/A4/23/2021 (Estimated)4/29/2021 (Confirmed)5/6/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableOptionable
SourceHeadline
FGEN EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of FibroGen, Inc. - Yahoo FinanceFGEN EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of FibroGen, Inc. - Yahoo Finance
finance.yahoo.com - April 18 at 7:29 AM
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - FGEN - Yahoo FinanceInvestor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - FGEN - Yahoo Finance
finance.yahoo.com - April 17 at 8:19 PM
FGEN EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of FibroGen, Inc.FGEN EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of FibroGen, Inc.
feeds.benzinga.com - April 17 at 4:55 PM
FGEN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm - Yahoo FinanceFGEN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm - Yahoo Finance
finance.yahoo.com - April 17 at 2:29 PM
FIBROGEN INVESTOR ALERT: Shareholder Class Action Lawsuit Filed - Yahoo FinanceFIBROGEN INVESTOR ALERT: Shareholder Class Action Lawsuit Filed - Yahoo Finance
finance.yahoo.com - April 17 at 2:29 PM
FIBROGEN INVESTOR ALERT: Shareholder Class Action Lawsuit FiledFIBROGEN INVESTOR ALERT: Shareholder Class Action Lawsuit Filed
finance.yahoo.com - April 17 at 2:29 PM
BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FGEN - Yahoo FinanceBREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FGEN - Yahoo Finance
finance.yahoo.com - April 17 at 8:43 AM
BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FGEN - GlobeNewswireBREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FGEN - GlobeNewswire
globenewswire.com - April 17 at 12:21 AM
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, GOEVW INVESTORS of Lead Plaintiff Deadline in Class Action LawsuitsSHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, GOEVW INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
finance.yahoo.com - April 17 at 12:20 AM
BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FGENBREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FGEN
benzinga.com - April 16 at 8:10 PM
Who Has Been Buying FibroGen, Inc. (NASDAQ:FGEN) Shares? - NasdaqWho Has Been Buying FibroGen, Inc. (NASDAQ:FGEN) Shares? - Nasdaq
nasdaq.com - April 16 at 7:20 PM
FibroGen Deadline Alert - Yahoo FinanceFibroGen Deadline Alert - Yahoo Finance
finance.yahoo.com - April 16 at 7:20 PM
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN - Yahoo FinanceFIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN - Yahoo Finance
finance.yahoo.com - April 16 at 9:19 AM
FIBROGEN INVESTOR ALERT: Class Action Lawsuit Filed - Yahoo FinanceFIBROGEN INVESTOR ALERT: Class Action Lawsuit Filed - Yahoo Finance
finance.yahoo.com - April 16 at 9:19 AM
LAWSUITS FILED AGAINST VLDR, FGEN and DDD - Jakubowitz Law Pursues Shareholders ClaimsLAWSUITS FILED AGAINST VLDR, FGEN and DDD - Jakubowitz Law Pursues Shareholders Claims
finance.yahoo.com - April 16 at 9:18 AM
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
finance.yahoo.com - April 16 at 9:18 AM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Approaching - Yahoo FinanceHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Approaching - Yahoo Finance
finance.yahoo.com - April 15 at 11:43 PM
FGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against FibroGen Inc. - Business WireFGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against FibroGen Inc. - Business Wire
businesswire.com - April 15 at 11:43 PM
Portnoy Law: Lawsuit Filed On Behalf of FibroGen, Inc. Investors - Yahoo FinancePortnoy Law: Lawsuit Filed On Behalf of FibroGen, Inc. Investors - Yahoo Finance
finance.yahoo.com - April 15 at 6:42 PM
SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders - Business WireSHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders - Business Wire
businesswire.com - April 15 at 6:42 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline ApproachingHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Approaching
finance.yahoo.com - April 15 at 6:42 PM
Lawsuits Filed Against VLDR, LDOS and FGEN - Jakubowitz Law Pursues Shareholders ClaimsLawsuits Filed Against VLDR, LDOS and FGEN - Jakubowitz Law Pursues Shareholders Claims
finance.yahoo.com - April 15 at 6:42 PM
Portnoy Law: Lawsuit Filed On Behalf of FibroGen, Inc. InvestorsPortnoy Law: Lawsuit Filed On Behalf of FibroGen, Inc. Investors
benzinga.com - April 15 at 2:52 PM
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm - Yahoo FinanceFGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm - Yahoo Finance
finance.yahoo.com - April 15 at 1:42 PM
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Business WireKessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Business Wire
businesswire.com - April 15 at 1:42 PM
FibroGen (NASDAQ:FGEN) Lifted to Neutral at JPMorgan Chase & Co.FibroGen (NASDAQ:FGEN) Lifted to Neutral at JPMorgan Chase & Co.
marketbeat.com - April 7 at 10:12 AM
FibroGen (NASDAQ:FGEN) Raised to "Buy" at Bank of AmericaFibroGen (NASDAQ:FGEN) Raised to "Buy" at Bank of America
marketbeat.com - March 31 at 7:42 AM
DateCompanyBrokerageAction
3/31/2021ArvinasBMO Capital MarketsInitiated Coverage
3/30/2021ArvinasCantor FitzgeraldBoost Price Target
1/19/2021ArvinasOppenheimerBoost Price Target
12/21/2020ArvinasPiper SandlerBoost Price Target
12/15/2020ArvinasCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/15/2020ArvinasSmith Barney CitigroupBoost Price Target
12/15/2020ArvinasRoth CapitalBoost Price Target
12/14/2020ArvinasHC WainwrightReiterated Rating
12/14/2020ArvinasThe Goldman Sachs GroupBoost Price Target
12/14/2020ArvinasWedbushBoost Price Target
3/22/2021I-MabNeedham & Company LLCInitiated Coverage
2/13/2020I-MabCICC ResearchInitiated Coverage
2/12/2020I-MabChina Renaissance SecuritiesInitiated Coverage
2/11/2020I-MabJefferies Financial GroupInitiated Coverage
7/29/2020HyperaHSBCUpgrade
3/8/2021Agios PharmaceuticalsJPMorgan Chase & Co.Reiterated Rating
3/4/2021Agios PharmaceuticalsSVB LeerinkReiterated Rating
1/27/2021Agios PharmaceuticalsBarclaysBoost Price Target
12/28/2020Agios PharmaceuticalsCanaccord GenuityLower Price Target
12/22/2020Agios PharmaceuticalsRoyal Bank of CanadaLower Price Target
4/13/2021FibroGenMizuhoReiterated Rating
4/7/2021FibroGenRaymond JamesReiterated Rating
3/31/2021FibroGenBank of AmericaUpgrade
5/1/2020FibroGenCowenInitiated Coverage
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.